References
Friedmann, T. in The Development of Human Gene Therapy (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1999).
Williamsburg BioProcessing Foundation Meeting, Viral Vectors and Vaccines, (The Williamsburg Bioprocessing Foundation, Norfolk, Virginia,1998).
Summerford, C. & Samulski, R.J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438–1445 (1998).
Wistuba, A., Kern, A., Weger, S., Grimm, D. & Kleinschmidt, J.A. Subcellular compartmentalization of adeno-associated virus type 2 assembly. J. Virol. 71, 1341–1352 (1997).
Grimm, D., Kern, A., Rittner, K. & Kleinschmidt, J.A. Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum. Gene Ther. 9, 2745–2760 (1998).
Zolotukhin, S. et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. (in the press).
Clark, K.R., Liu, X., McGrath, J.P. & Johnson, P.R. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild type viruses. Hum. Gene Ther. (in the press).
Xiao, X., Li, J. & Samulski, R.J. Production of high titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72, 2224–2232 (1998).
Clark, K.R., Voulgaropoulou, F., Fraley D.M., & Johnson, P.R. Cell lines for the production of infectious recombinant adeno-associated viruses. Hum. Gene Ther. 6, 1329–1341 (1995).
Summerford, C., Bartlett, J.S. & Samulski, R.J. αVβ5 integrin: A co-receptor for adeno-associated virus type 2 infection. Nature Med. 5, 78–81 (1999).
Qing, K. et al. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nature Med. 5, 71–77 (1999).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Summerford, C., Samulski, R. Viral receptors and vector purification: New approaches for generating clinical-grade reagents. Nat Med 5, 587–588 (1999). https://doi.org/10.1038/8470
Issue Date:
DOI: https://doi.org/10.1038/8470
- Springer Nature America, Inc.
This article is cited by
-
Pharmaceutical Development of AAV-Based Gene Therapy Products for the Eye
Pharmaceutical Research (2019)
-
Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury
Acta Neuropathologica Communications (2015)
-
RANGE: Gene Transfer of Reversibly Controlled Polycistronic Genes
Molecular Therapy - Nucleic Acids (2013)
-
Downstream processing of viral vectors and vaccines
Gene Therapy (2005)
-
Receptor targeting of adeno-associated virus vectors
Gene Therapy (2003)